Mechanistic insights into effects of the cardiac myosin activator omecamtiv mecarbil from mechanokinetic modelling.

ABSTRACT:

Introduction

Small molecular compounds that affect the force, and motion-generating actin-myosin interaction in the heart have emerged as alternatives to treat or alleviate symptoms in severe debilitating conditions, such as cardiomyopathies and heart failure. Omecamtiv mecarbil (OM) is such a compound developed to enhance cardiac contraction. In addition to potential therapeutic use, its effects may help to elucidate myosin energy transduction mechanisms in health and disease and add insights into how the molecular properties govern contraction of large myosin ensembles in cardiac cells. Despite intense studies, the effects of OM are still incompletely understood.

Methods

Here we take an in silico approach to elucidate the issue. First, we modify a model, previously

SUBMITTER: Mansson A 

PROVIDER: S-EPMC12043640 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature